Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for cognitive impairment in Parkinson's disease
2026-525701-12-00Phase 2Withdrawn
- Sponsor
- Universidad Rey Juan Carlos
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) and Mild Cognitive Impairment (MCI) comparing Methylphenidate Viatris with Placebo (saccharine tablets) (2 arms). Primary endpoints: Electrophysiological markers, Neuropsychological evaluation and 2 more. Planned start Jun 2026; status: withdrawn.
02
Drugs
methylphenidate
03
Conditions
Parkinson's disease (PD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2026-525701-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525701-12-00.